Advanced

Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer.

Kreimer, Aimée R; Johansson, Mattias; Waterboer, Tim; Kaaks, Rudolf; Chang-Claude, Jenny; Drogen, Dagmar; Tjønneland, Anne; Overvad, Kim; Quirós, J Ramón and González, Carlos A, et al. (2013) In Journal of Clinical Oncology 31(21). p.2708-2708
Abstract
PURPOSEHuman papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. METHODSWe identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed... (More)
PURPOSEHuman papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. METHODSWe identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression.ResultsHPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. CONCLUSIONHPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Oncology
volume
31
issue
21
pages
2708 - 2708
publisher
American Society of Clinical Oncology
external identifiers
  • pmid:23775966
  • wos:000330538700019
  • scopus:84883134703
ISSN
1527-7755
DOI
10.1200/JCO.2012.47.2738
language
English
LU publication?
yes
id
828aa1b0-5b2f-47a3-b23c-d915d321846d (old id 3913253)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23775966?dopt=Abstract
date added to LUP
2013-07-01 13:55:41
date last changed
2019-08-14 03:02:52
@article{828aa1b0-5b2f-47a3-b23c-d915d321846d,
  abstract     = {PURPOSEHuman papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. METHODSWe identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression.ResultsHPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. CONCLUSIONHPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.},
  author       = {Kreimer, Aimée R and Johansson, Mattias and Waterboer, Tim and Kaaks, Rudolf and Chang-Claude, Jenny and Drogen, Dagmar and Tjønneland, Anne and Overvad, Kim and Quirós, J Ramón and González, Carlos A and Sánchez, Maria José and Larrañaga, Nerea and Navarro, Carmen and Barricarte, Aurelio and Travis, Ruth C and Khaw, Kay-Tee and Wareham, Nick and Trichopoulou, Antonia and Lagiou, Pagona and Trichopoulos, Dimitrios and Peeters, Petra H M and Panico, Salvatore and Masala, Giovanna and Grioni, Sara and Tumino, Rosario and Vineis, Paolo and Bueno-de-Mesquita, H Bas and Laurell, Göran and Hallmans, Göran and Manjer, Jonas and Ekström, Johanna and Skeie, Guri and Lund, Eiliv and Weiderpass Vainio, Elisabete and Ferrari, Pietro and Byrnes, Graham and Romieu, Isabelle and Riboli, Elio and Hildesheim, Allan and Boeing, Heiner and Pawlita, Michael and Brennan, Paul},
  issn         = {1527-7755},
  language     = {eng},
  number       = {21},
  pages        = {2708--2708},
  publisher    = {American Society of Clinical Oncology},
  series       = {Journal of Clinical Oncology},
  title        = {Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer.},
  url          = {http://dx.doi.org/10.1200/JCO.2012.47.2738},
  volume       = {31},
  year         = {2013},
}